cariprazine VRAYLAR

Class: Second Generation Antipsychotic
FDA Indications: Schizophrenia, Bipolar Mania
Off-Label Use: Behavioral And Psychological Symptoms Of Dementia
Forms: 1.5, 3, 4.5, 6mg capsule
Dose Range: 1.5-6 mg/day
Starting: 1.5 mg qd, then titrate up to 3-6 mg qd
Stopping: Taper 6-8 weeks, rapid d/c can lead to rebound psychosis

NAMI drug fact sheet

Serious Side Effects: , , ,
Not in CredibleMeds's database at this time.
Side Effects: sedation/somnolence, dizziness, constipation, insomnia, akathisia, vomiting, EPS, dyspepsia, restlessness
1° MOA: D3-preferring D3/D2 receptor partial agonist
Target: Partial agonism at: Antagonism at:
t½: 48 (31-69)° TMAX: 3-4°
Substrate of: 3A4; 2D6
Inhibits: ∅ ; Induces:
Active Metabolites: desmethyl-cariprazine (DCAR) & didesmethyl-cariprazine (DDCAR)
  • - t½ of combined drug (parent compound and its 2 active metabolites) is ~1 week
  • - shows preference for D3 receptors over D2 receptors
  • - minimal effect on prolactin
  • - relative lack of effect on metabolic parameters, including weight
Special Populations

Category Not assigned.—There are no available data on VRAYLAR use in pregnant women to inform any drug-associated risks for birth defects or miscarriage.

It is not known if cariprazine is excreted in breast milk.

All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo.

No dosage adjustment necessary

Mild to moderate impairment: No dosage adjustment necessary; Severe impairment: Use not recommended


Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated February 07 2019 16:52:18. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.